SOUTH SAN FRANCISCO, Calif., September 22, 2021 – GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has added two accomplished industry executives to its leadership team. The company has appointed Romuald Corbau, Ph.D., as Chief Scientific Officer (CSO) and Aaron Mishel as Chief Financial Officer (CFO).
As part of his 20-plus years of drug discovery and development experience, Dr. Corbau led the translation of innovative genetic medicine therapies into clinical development at Spark Therapeutics and Freeline. Mr. Mishel brings to GenEdit more than twenty years of healthcare sector experience across various leadership positions in finance, operations, corporate development, and investment banking equity research.
“The expansion of the management team comes at a pivotal time for GenEdit as we further develop our NanoGalaxyTM platform to enable genetic medicine delivery and select therapeutic candidates for clinical development,” said Kunwoo Lee, Ph.D., GenEdit’s CEO and Co-founder. “Romu and Aaron bring a depth of experience and expertise that will be invaluable as we build our company, platform, and pipeline to advance new treatments internally and with partners for a broad range of diseases with unmet medical needs.”
Dr. Corbau joins GenEdit from Freeline, where he led the research organization and built differentiated systemic gene therapy capabilities. Before Freeline, he was the Translational Lead at Spark Therapeutics. At both companies, Dr. Corbau was focused on the discovery and development of AAV-based gene therapies. Prior to that, he was Director of Biology at the Center for Innovation and Stimulation of Drug Discovery. Dr. Corbau began his pharmaceutical career at Pfizer Global Research & Development.
“GenEdit has a truly convincing approach to the delivery of genetic medicines that offers advantages over other vector systems,” added Dr. Corbau. “The team has demonstrated that NanoGalaxy polymer nanoparticles can achieve the delivery of a wide range of payloads to target tissues and can be successfully redosed. I look forward to working with the team to explore all the possibilities within NanoGalaxy to develop innovative therapies that will benefit as many patients as possible.”
Prior to joining GenEdit, Mr. Mishel served as the Chief Financial Officer of Magnetic Insight. Previously, he was the Head of Finance for Modis Therapeutics, where he helped lead the company’s sale to Zogenix. Prior to Modis, he was Director of Business & Corporate Development at BioMarin Pharmaceutical. Mr. Mishel also worked in Equity Research at Deutsche Bank and Thomas Weisel Partners, where he covered the specialty pharmaceuticals industry.
Mr. Mishel concluded, “I am thrilled to be joining GenEdit at this important stage as the company transitions its focus from demonstrating proof-of-concept for the platform to selecting initial therapeutic programs for clinical development. I look forward to working with the GenEdit team to ensure that the company’s platform technology and therapeutic programs realize their full potential.”
About GenEdit, Inc.
At GenEdit, our mission is to develop curative therapies through targeted in vivo delivery of genetic medicines. Our NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles will enable a universe of opportunities to launch the next generation of safe and effective genetic medicines. To bring these medicines to patients, we are developing our own internal pipeline and delivering a wide variety of therapeutic payloads for our partners’ programs. For more info, visit www.genedit.com.
Company Contact: Kunwoo Lee, Ph.D., GenEdit, Inc., email@example.com, +1 (510) 766-2575
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org, +1 (858) 344-8091